Genzyme Corporation Selects Ariba Spend Management Tools
Ariba(R), Inc., the leading Enterprise Spend Management (ESM) solutions provider, announced that Genzyme Corporation, a global biotechnology company, has selected Ariba(R) Buyer(TM), Ariba(R) Enterprise Sourcing(TM), and services from Ariba’s Solutions Delivery (ASD) team to improve management of the company’s corporate-wide spend and streamline its procurement processes.
With more than 25 major products and services helping patients in more than 80 countries, Genzyme is developing and applying the most advanced capabilities in biotechnology today to address a range of unmet medical needs. In order to achieve these goals, Genzyme sought a way to reduce operational costs to increase bottom line savings.
After evaluating approximately 20 vendors, Genzyme selected Ariba Buyer and Ariba Enterprise Sourcing as part of a strategic initiative to drive down procurement costs, establish new process efficiencies, automate procurement and sourcing, establish more advantageous pricing, and renegotiate contracts on a global basis. Ariba solutions presented the most mature solution set, and the Ariba Service Delivery team (ASD) offered significant consulting experience in the biotechnology area.
Genzyme plans to roll out Ariba Enterprise Spend Management (ESM) tools in both North America and Europe to automate its sourcing and procurement processes. Genzyme will leverage the experience of the ASD team to help meet its corporate-wide cost-reduction goals. ASD will provide functional and technical best practice knowledge and experience to help enable Genzyme achieve its strategic business objectives.
“Genzyme is committed to implementing a spend management strategy to meet core business objectives and further increase the company’s ability to fund innovative biomedical research and development,” said Michael Schmitt, EVP Marketing and Strategy, Ariba. “We are extremely pleased to add Genzyme to our list of leading biotech customers and we are committed to helping the company achieve measurable savings to further its sustainable research success.”
About Genzyme Corporation
Genzyme Corporation is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. The company’s broad product portfolio is focused on rare genetic disorders, renal disease, osteoarthritis and immune-mediated diseases, and includes an industry-leading array of diagnostic products and services. Genzyme’s commitment to innovation continues today with research into novel approaches to cancer, heart disease, and other areas of unmet medical need. More than 5,600 Genzyme employees in offices around the globe serve patients in over 80 countries.
About Ariba, Inc.
Ariba, Inc. is the leading Enterprise Spend Management (ESM) solutions provider. Ariba helps companies develop and leverage spend management as a core competency to drive significant bottom line results. Ariba Spend Management software and services allow companies to align their organizations with a spend-centric focus and deploy closed-loop processes for increased efficiencies and sustainable savings. Ariba can be contacted in the U.S. at 1 650-390-1000 or at www.ariba.com .
Ariba and the Ariba logo are registered trademarks of Ariba, Inc. Ariba Spend Management, Ariba Analysis, Ariba Buyer, Ariba Category Management, Ariba Contracts, Ariba Travel & Expense, Ariba Workforce, Ariba Invoice, Ariba eForms, Ariba Enterprise Sourcing, Ariba Supplier Network, BPM Services, Power Sourcing, Total Spend Capture and PO-Flip are trademarks or service marks of Ariba, Inc. All other trademarks are property of their respective owners.
Ariba Safe Harbor
Safe Harbor Statement under the Private Securities Litigation Reform Act 1995: Information and announcements in this release involve Ariba’s expectations, beliefs, hopes, plans, intentions or strategies regarding the future and are forward-looking statements that involve risks and uncertainties. All forward-looking statements included in this release are based upon information available to Ariba as of the date of the release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to Ariba’s operating and financial results to differ materially from its current expectations include, but are not limited to: delays in development or shipment of new versions of Ariba’s products and services; lack of market acceptance of Ariba’s existing or future products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; the ability to attract and retain qualified employees; difficulties in assimilating acquired companies; the impact of recent workforce reductions on Ariba’s operations; lengthening sales cycles and the deferrals of anticipated orders; declining economic conditions, including a recession; inability to control costs; changes in the company’s pricing or compensation policies; inability to successfully manage a reduction in the company’s workforce; significant fluctuations in our stock price; the outcome of legal proceedings relating to the restatement of our financial statements; the possibility that stockholders or regulatory authorities may initiate additional proceedings against Ariba and/or our officers and directors as a result of the restatements; the impact of acquiring Alliente and entering into an agreement to acquire FreeMarkets, including the disruption or loss of customer, business partner, supplier or employee relationships; the level of costs and expenses incurred by Ariba as a result of such transactions; and the level of professional fees and expenses incurred by Ariba in connection with its previously disclosed accounting review and associated regulatory and litigation proceedings. Factors and risks associated with its business, including a number of the factors and risks described above, are discussed in Ariba’s Form 10-K/A filed January 28, 2004 and in its Form S-4 filed April 2, 2004.
